Despite the threat of coronavirus infection, the Siddha system of medicine, India's traditional medicine, plays an important role in southern India, particularly in Tamilnadu. It contributed considerably not only in the first wave of Covid-19, but also in the second wave. The Government of Tamilnadu developed Siddha COVID-19 treatment centers for asymptomatic, mild, and moderate COVID-19 positive patients in 2020. The TPEC COVID Care Centre initiated at Vellore also one of the Centers that can be managed by Siddha medicines and Siddhar’s Yogam. As of July 14, 2021, about 4525 COVID positive patients had been treated with Siddha integrated treatment at Vellore alone in the first and second waves. Kaba Sura Kudineer, Thalisathy Vadagam, Amukkara Chooranam Mathirai, Bramanandha Bairavam Mathirai, and Adathodai Manapagu are indeed the five Siddha classical preparations used to manage the symptoms of COVID-19 positive patients at TPEC COVID Care Centre in Vellore. This Siddha medical practice is effective in conditions of symptoms and helps in the reduction of clinical outcomes. A pilot study at the same site confirmed the Siddha classical preparation's safety and effectiveness. A feedback analysis study performed at the same center also revealed that the above-mentioned Siddha classical preparations are beneficial in symptomatic treatment without causing any side effects. The medicines utilized in this study are typically proposed in other COVID care centers also in Tamilnadu. This review attempted to analyze the preclinical and clinical efficacy of Siddha Classical medicines used at that Centre for the management of COVID-19.
Background: Covid-19 disease is a Wuhan, China originated acute viral respiratory illness. Even though the development of numerous vaccines, the threat of the Covid-19 virus endures nearly two years after the outbreak. The new mutant strain omicron has now spread to several countries. As a result, newer antiviral therapy is required to overcome this scenario. Objective: This study is aimed at phytocomponents in the Siddha formulation, Vishasura Kudineer (VSK), it is widely used to manage fever and respiratory ailments and may be effective in combating the ongoing pandemic of novel coronavirus disease. Methodology: The principal protease 3CLpro of this new Coronavirus (SARS-CoV-2) is a possible focus for therapeutic development since it plays a major part in disease transmission. Molecular docking investigation for all active Phytocomponents found in the Siddha formulation Vishasura Kudineer with possible targets was carried in the major Protease of SARS-CoV-2 (PDB ID:6LU7). AutoDockTools was used to design and optimize the ligand structures. Results: Molecular docking of the 9 bioactive phytocomponents as Santalic acids (-6.39), Nimbolide (-6.38), Rutin, Aristolochic acid (-6.95), Glabridin (-7.53), Indirubin (-7.23), Sabinene (-5.36), β-vetivenene (-6.79), and Zingiberene (-6.47) from in the Siddha sastric formulation, Vishasura Kudineer performed on the SARS-CoV-2 Main Protease protein’s active site (PDB ID: 6LU7). These phytochemicals had significant molecular interaction with the active residues, indicating their distinct inhibitory potencies. Conclusion: Whether this Siddha formulation could be used to effectively treat and manage COVID-19 and its variants, further research and clinical studies need to be done.
Background: In December of 2019, mysterious pneumonia was reported. A novel coronavirus (nCoV) was identified as the causative agent for this pneumonia; it is now known as coronavirus 2. This pandemic has caused widespread alarm around the world. Now, countries around the world are preparing for the third and fourth waves of COVID-19. Objective: This research aims to conduct In Silico computational studies of phytoconstituents in leaf extracts of the Siddha medicinal herb Aegle marmelos (Vilvam), which are commonly used in the treatment of viral fever and respiratory infectious diseases and may be effective against the current pandemic novel coronavirus disease. Methodology: In Silico molecular docking analysis was performed for all the active compounds present in the herb Aegle marmelos (Vilvam) with potential targets SARS-CoV-2 Main Protease (PDB ID: 7JQ5). The ligand structures were prepared and optimized by AutoDockTools. The active sites docking study was performed using Autodock Vina for all the compounds. The inhibitor compound MPI8 bound inSARS-CoV-2 main protease Protein-Ligand complex (PDB ID: 7JQ5) is considered as the reference inhibitor molecule of this study. Results: Molecular docking of the 14 bioactive phytochemicals compounds from Aegle marmelos leaves carried out towards the active site of SARS-CoV-2 Main Protease protein (PDB ID: 7JQ5). The interactions of these compounds were comparatively analyzed with the reference inhibitor MPI8 bound inSARS-CoV-2 Main Protease protein-ligand complex (PDB ID: 7JQ5). These phytochemicals exhibited effective molecular interactions with the active residues enumerating their differential inhibition potency. Conclusion: Further research and clinical trials are needed whether this herb can be implemented to effectively treat and manage COVID-19.
Covid-19 is a novel virus that occurs in humans and travels globally very rapidly from person to person. Coronavirus disease is a critical challenge in high population countries such as India. The rising expense of western medicine and its adverse reactions has become an important challenge against Covid-19. Nowadays the traditional medical system and its preparations are for various ailments becoming more popular. South Asia's one of the ancient medicine is the Siddha system of medicine. Kaba Sura Kudineer (KSK) has become a popular Siddha medicine on this pandemic. Previously, Nilavembu Kudineer (NVK) is being used more often during dengue fever, Chikungunya, and swine flu outbreaks, which reduced the mortality rate also. Some other medicines, too, are immensely beneficial. Due to a lack of modern antiviral medications, conventional medical systems in respective countries are now becoming known therapeutics, as a consequence of the pandemic. The second wave of Covid-19 is more virulent than the previous first wave. When compared to the previous, the rate of infection transmission and mortality was also higher. Over the next months, India will be targeted by the third and fourth waves of the Coronavirus infection, posing a greater threat to public health. As a result, some Siddha medicines which are administered and observed in Covid Care Centers reported satisfactory clinical outcomes and feedback reports. To justify the formulations, an attempt has been carried out to analyze the ingredients of medicines using textual evidence. This will enable researchers to evaluate the formulations to explore them in further research.
Siddha's system of medicine is the effective one to reduce the symptoms of many viral illnesses. Siddha's system of medicine in asymptomatic, mild to moderate Covid-19 Positive patients, will make them recognize its effectiveness, reduce the symptoms, and move into the traditional approach towards the deadliest pandemic disease Covid-19. The objective of this study is to evaluate the acceptance and benefit of integrative Siddha management among the mild, moderate and asymptomatic COVID patients through a feedback questionnaire in TPEC COVID Care Center, Vellore, Tamil Nadu (TPECThanthai Periyar Engineering College). 74 asymptomatic, mild to moderate Covid-19 Positive patients were observed 7 days from 14.07.2020 to 30.07.2020 in TPEC COVID Care Center, Vellore, Tamil Nadu. During this period, Siddha medicines were administrated along with Western medicine. At the end of the period, validated feedback questionnaires were used to collect information from 74 participants for evaluating the acceptance and benefit of integrative Siddha management.In the 74 patients of TPEC COVID Care Center, Vellore, 100% were taken the given Siddha drug properly. 82.4% had the most common symptoms and 52.7% had less common symptoms. 16.2% of cases developed gastric acidity and 1.3% developed mild dyspnea as an ADR. 91.8% were recommended the Siddha system to others. 93.2% reported excellent disease progress. 90.7% of Siddha doctors quoted for 'Excellent' service on covid patients. This feedback report explores the three important significance. (a) Siddha medicine having significant effectiveness (b) Siddha medicines have safety in covid-19 patients (c) overall services of Siddha doctors are appreciatable by the patients and Siddha system is recommended to others. This analysis report helps to provide the possibility of the Siddha system for further or future clinical trials.
Background: Covid-19 is a global pandemic since 2019. SARS-CoV2 is a new virus that originated from China and is currently spread across 160 countries. Siddha medicine is one of the traditional Indian medicines, part of Ayush that tend to treat several acute and chronic diseases. Aim: The objective of this study is to observe the safety and efficacy of Siddha regimen with lab parameters like LFT, RFT, RT-PCR, LDH, FERRITIN levels, and prevention of disease complications in covid-19 positive patients on the 7th day of treatment. Experimental Procedure: A non-randomized open-label observational retrospective study was designed. Twenty patients of either sex, of age between 18 and 60 years, were selected with proper consent. The covid patients who were confirmed by positive RT-PCR test results with or without clinical features of covid-19 were selected. They were treated with Siddha Regimen for seven days. Results: Sixteen out of 20 cases turned RT-PCR negative on their 7th day of treatment. And the Ct value of RT-PCR was statistically significant. LDH and Ferritin levels were reduced after the treatment even though the before treatment values are in the normal range. The LDH level was statistically significant on the 7th day of treatment. No Remarkable changes in the safety laboratory parameters like SGOT, SGPT, Blood urea, Serum Creatinine. Conclusion: Significant changes in efficacy laboratory parameters and no changes in safety laboratory parameters have been reported in the Siddha fixed regimen for covid-positive patients. All the 20 study participants were recovered without emergency and hospitalization.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.